Background: Background activity on fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) is often used as a reference to assess a patient’s response to tumor treatment. To produce a suitable background activity reference, we examined the variations in standardized uptake values (SUVs) in the blood pool and liver of a large multi-aged population. Methods: A total of 2,526 subjects underwent 18F-FDG PET/CT examinations and were divided into 12 age groups. Pearson’s partial correlation and multivariate regression analyses were performed to assess the associations between individual factors and SUVs of the blood pool and liver and to identify the factor that most influenced the SUVs. The mean SUVs across the age groups were also determined. Results: Positive correlations were found between individual factors and SUVs. Age appeared to be the most important predictor of SUVs and was significantly associated with the blood pool SUVmax (ß=0.466, P=0.000), blood pool SUVmean (ß=0.393, P=0.000), liver SUVmax (ß=0.347, P=0.000), and liver SUVmean (ß=0.354, P=0.000). Blood pool and liver SUVs rose rapidly until the age of 20 and then showed a slow upward trend without reaching a plateau. Conclusions: Age is an important factor that influences variations in the blood pool and liver SUVs. Our study clarified this understanding of age-related variations in SUVs and provided a normal range of blood pool and liver SUVs that may aid clinicians in evaluating tumors with greater accuracy.
Background: The etiology of fever of unknown origin (FUO) is complex, and early diagnosis of FUO is important for determining the method of treatment, but there are no uniform diagnostic criteria. This study aimed to evaluate the value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in differentiating the etiological types of FUO and to develop a predictive model. Methods: A total of 456 FUO patients with baseline 18F-FDG-PET/CT data were enrolled. The etiological categories were classified into neoplastic diseases (NDs) and nonneoplastic diseases (NNDs) and then classified into infectious diseases (IDs) and noninfectious inflammatory diseases (NIIDs). Continuous variables were compared with the Mann-Whitney U test, and categorical variables were compared with the Chi-squared test. Features were screened via the above method, and multivariate logistic regression (Bonferroni correction) was subsequently applied to construct two models: a clinical model (laboratory data only) and a combined model (laboratory + PET/CT data), with corresponding nomograms generated. The model performance was assessed by calculating the area under the receiver operating characteristic curve (AUC), which was compared via the Delong test. Results: To differentiate between NDs and NNDs, five PET/CT variables [asymmetrical distribution of hypermetabolic lymph nodes, maximum standardized uptake value (SUVmax) in the bone marrow, SUVmax in the spleen, splenomegaly, and focal liver lesion], and three laboratory variables [white blood cell (WBC) count, platelet count (PLT) and lactate dehydrogenase (LDH)] (all P<0.05) were selected to construct the models. To differentiate between IDs and NIIDs, three PET/CT variables (short diameter of the lymph node, hypermetabolic spleen, and focal spleen lesion), one laboratory variable (WBC count) and age (all P<0.05) were selected to construct the models. In the validation group, the combined model (AUC =0.742) did not demonstrate significant improvement over the clinical model—either in differentiating NDs from NNDs (AUCcombined =0.742 vs. AUCclinical =0.680; P=0.080) or in distinguishing ID from NIID (AUCcombined =0.737 vs. AUCclinical =0.678; P=0.111). Conclusions: This study demonstrated the diagnostic value of 18F-FDG PET/CT in differentiating etiological types of FUO. However, the addition of 18F-FDG PET/CT did not significantly enhance the ability of clinical models to distinguish between NDs and NNDs or between IDs and NIIDs. Further validation in future studies is warranted.
The relapses of rectal cancer are most frequently localized in the pelvis, liver, and pelvic and para-aortic lymph nodes and lungs, whereas the vagina is an unusual site. We present here a 60-year-old woman presenting with lower abdominal discomfort 23 months after radical resection of rectal adenocarcinoma. An isolated, solitary, hypermetabolic mass in the right part of the vagina was detected by 18F-FDG PET/CT. Ultimately, the vaginal neoplasm was proved to be adenocarcinoma of rectal origin based on its shared histologic features and compatible immunostaining profile.
Introduction: Accurate baseline clinical staging is critical to inform treatment decision-making for patients with gastric cancers. Peritoneal metastasis (PM) is the most common form of metastasis in gastric cancer and mainly diagnosed by diagnostic laparoscopy and peritoneal lavage evaluation. However, diagnostic laparoscopy is invasive and less cost-effective. It is urgent to develop a safe, fast and non-invasive functional imaging method to verify the peritoneal metastasis of gastric cancer. The aim of our study was to evaluate the proportion of patients in whom68Ga-FAPI-04 positron emission tomography/CT (PET/CT) led to a change in treatment strategy and to assess the diagnostic accuracy of68Ga-FAPI-04 PET/CT for the detection of occult peritoneal metastasis compared with laparoscopic exploration.Methods and analysis: In this single-centre, prospective diagnostic test accuracy study, a total of 48 patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma (cT4a-b, N0-3, M0, based on CT images) who are considering radical tumour surgery will be recruited. All participants will undergo68Ga-FAPI-04 PET/CT before the initiation of laparoscopic exploration. The primary outcome is the proportion of patients with occult peritoneal metastatic lesions detected by68Ga-FAPI-04 PET/CT, leading to a change in therapy strategy. The secondary outcomes include the diagnostic performance of68Ga-FAPI-04 PET/CT for occult peritoneal metastasis, including sensitivity, specificity, accuracy, positive predictive value and negative predictive value.Ethics and dissemination: The study protocol was approved by the Ethics Committee of West China Hospital, Sichuan University (2022-1484). Study results will be presented at public and scientific conferences and in peer-reviewed journals.Trial registration number: ChiCTR2300067591.